Short Interest in BioCardia, Inc. (NASDAQ:BCDA) Declines By 62.1%

BioCardia, Inc. (NASDAQ:BCDA) was the target of a large decrease in short interest in October. As of October 15th, there was short interest totalling 50,000 shares, a decrease of 62.1% from the September 30th total of 132,100 shares. Based on an average daily volume of 821,600 shares, the days-to-cover ratio is presently 0.1 days. Approximately 1.8% of the shares of the stock are sold short.

BioCardia Stock Up 0.8 %

Shares of BioCardia stock opened at $2.42 on Monday. The stock has a market cap of $4.41 million, a price-to-earnings ratio of -0.34 and a beta of 1.26. BioCardia has a twelve month low of $1.96 and a twelve month high of $23.25. The company’s fifty day moving average is $2.75 and its 200 day moving average is $3.64.

BioCardia (NASDAQ:BCDA) last released its quarterly earnings results on Tuesday, August 13th. The company reported ($0.88) EPS for the quarter, missing analysts’ consensus estimates of ($0.10) by ($0.78). As a group, equities analysts anticipate that BioCardia will post -5.06 earnings per share for the current fiscal year.

Analyst Ratings Changes

Separately, HC Wainwright raised their target price on shares of BioCardia from $4.00 to $25.00 and gave the company a “buy” rating in a research report on Friday, August 16th.

BioCardia Company Profile

BioCardia, Inc, a clinical-stage regenerative medicine company, develops cellular and cell-derived therapeutics for cardiovascular and pulmonary diseases in the United States. Its lead product candidate is CardiAMP, an autologous mononuclear cell therapy system in Phase III clinical trial for the treatment of ischemic heart failure with reduced ejection fraction and refractory angina resulting from chronic myocardial ischemia.